Hims & Hers Novo Nordisk Partnership Reported
Reports say Hims & Hers Novo Nordisk partnership would let Hims sell Wegovy and Ozempic via telehealth and could alter revenue mix and positioning.
KEY TAKEAWAYS
- Reported partnership would let Hims & Hers sell branded Wegovy and Ozempic via its telehealth platform.
- The deal reportedly resolved Novo Nordisk's lawsuit over compounded semaglutide.
- Shifting to branded GLP-1s could change revenue mix and add supply and regulatory dependencies.
HIGH POTENTIAL TRADES SENT DIRECTLY TO YOUR INBOX
Add your email to receive our free daily newsletter. No spam, unsubscribe anytime.
Hims & Hers Health (HIMS) was reported on March 9, 2026, to have entered a partnership with Novo Nordisk (NVO) allowing its telehealth platform to offer branded weight-loss drugs Wegovy and Ozempic. The deal resolves a prior patent dispute and creates new supply and regulatory dependencies.
Partnership and Product Scope
In February 2026, Hims & Hers and Novo Nordisk reportedly reached an agreement permitting Hims & Hers to sell branded GLP-1 drugs Wegovy and Ozempic through its telehealth platform. This arrangement ended a lawsuit by Novo Nordisk challenging Hims & Hers’ earlier sales of compounded semaglutide products, which are generic versions of GLP-1 therapies. The company is shifting from compounded semaglutide offerings to branded GLP-1 drugs, introducing new supply and regulatory risks for its telehealth business.
Regulatory and Financial Implications
Reports of the partnership circulated on March 9, 2026, at ET timestamps 05:45, 06:06, 06:33, and 07:04. Hims & Hers’ 2026 revenue guidance, issued before the reported deal, projected between $2.7 billion and $2.9 billion based on weight-loss, sexual-health, lab-testing, and cancer-screening businesses. The partnership and shift to branded GLP-1 products could alter the company’s revenue mix and regulatory exposure relative to that guidance. Novo Nordisk had previously sued Hims & Hers over compounded semaglutide sales but shelved the lawsuit amid FDA scrutiny of compounded GLP-1 formulations, including an oral version of Wegovy that Hims & Hers abandoned. The new deal introduces regulatory oversight tied to branded obesity medications.
